C
Carolyn A. Holland
Researcher at Walter Reed Army Institute of Research
Publications - 12
Citations - 1243
Carolyn A. Holland is an academic researcher from Walter Reed Army Institute of Research. The author has contributed to research in topics: RTS,S & Malaria vaccine. The author has an hindex of 12, co-authored 12 publications receiving 1198 citations.
Papers
More filters
Journal ArticleDOI
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya.
Bernhards Ogutu,Odika J. Apollo,Denise McKinney,Willis Okoth,Joram Siangla,Filip Dubovsky,Kathryn Tucker,John N. Waitumbi,Carter L. Diggs,Janet Wittes,Elissa Malkin,Amanda J. Leach,Lorraine Soisson,Jessica Milman,Lucas Otieno,Carolyn A. Holland,Mark E. Polhemus,Shon Remich,Christian F. Ockenhouse,Joe Cohen,W. Ripley Ballou,Samuel K. Martin,Evelina Angov,V. Ann Stewart,Jeffrey A. Lyon,D. Gray Heppner,Mark R. Withers +26 more
TL;DR: FMP1/AS02 had a good safety profile and was well-tolerated but more reactogenic than the comparator, and is not a promising candidate for further development as a monovalent malaria vaccine.
Journal ArticleDOI
Long-Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria Vaccine
José A. Stoute,Kent E. Kester,Urszula Krzych,Bruce T. Wellde,Ted Hall,Katherine White,G Glenn,Christian F. Ockenhouse,N. Garcon,Robert Schwenk,David E. Lanar,P Sun,P Momin,Robert A. Wirtz,C Golenda,Moncef Mohamed Slaoui,Glenn Wortmann,Carolyn A. Holland,Megan Dowler,Joe Cohen,William Ripley Ballou +20 more
TL;DR: Further optimization in vaccine composition and/or immunization schedule will be required to induce longer-lasting protective immunity in malaria sporozoite vaccine candidate RTS,S.
Journal ArticleDOI
Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
Kent E. Kester,James F. Cummings,Christian F. Ockenhouse,Robin Nielsen,B. Ted Hall,Daniel M. Gordon,Robert Schwenk,Urszula Krzych,Carolyn A. Holland,Gregory Richmond,Megan Dowler,Jackie Williams,Robert A. Wirtz,Nadia Tornieporth,Laurence Vigneron,Martine Delchambre,Marie-Ange Demoitié,W. Ripley Ballou,Joe Cohen,D. Gray Heppner +19 more
TL;DR: In malaria-naïve adults, the efficacy of three-dose RTS,S/AS02 regimens on either a 0, 1, and 3 month schedule or an abbreviated 0, 7, and 28 day schedule was not discernibly different from two previously reported trials of two-dose regimens given at 0,1 month that conferred protection.
Journal ArticleDOI
Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya.
José A. Stoute,Joash Gombe,Mark R. Withers,Joram Siangla,Denise McKinney,Melanie Onyango,James F. Cummings,Jessica Milman,Kathryn Tucker,Lorraine Soisson,V. Ann Stewart,Jeffrey A. Lyon,Evelina Angov,Amanda J. Leach,Joe Cohen,Kent E. Kester,Christian F. Ockenhouse,Carolyn A. Holland,Carter L. Diggs,Janet Wittes,D. Gray Heppner +20 more
TL;DR: The FMP1/AS02A vaccine is safe and immunogenic in adults and should progress to safety testing in children at greatest risk of malaria.
Journal ArticleDOI
A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia.
J. F. Doherty,Margaret Pinder,Nadia Tornieporth,C. Carton,Laurence Vigneron,Paul Milligan,William Ripley Ballou,Carolyn A. Holland,Kent E. Kester,Gerald Voss,P Momin,Brian Greenwood,Keith P. W. J. McAdam,Joe Cohen +13 more
TL;DR: It is concluded that the RTS,S/SBAS2 vaccine induces no significant toxicity in this semi-immune population and produces significant increases in antibody titers to CSP.